To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
History of analytical measuring technology in Jena
Analytik Jena opens company museum
19-06-2013
Analytik Jena AG's company museum presents the history of analytical measuring technology in Jena to visitors, customers, business partners and interested guests over 70 square meters, and showcases the continuation of instrument development at Analytik Jena up to the present day. More than ...
Malvern Instruments announces global agreement with Proveris Scientific
22-05-2013
Malvern Instruments has announced an agreement with Proveris Scientific Corporation to provide a complete solution for nasal spray characterization. This solution comprises the SoloTM for Spraytec system (Proveris), a patented automated actuator and software for the control of the actuation ...
Analytik Jena to develop products for sepsis diagnostics
All assets taken over from insolvent company SIRS-Lab GmbH
08-05-2013
Analytik Jena has acquired all of the assets of the insolvent company SIRS-Lab GmbH as part of an asset deal. SIRS-Lab, a company that develops molecular diagnostics methods and testing systems for life-threatening infections like sepsis, had filed for insolvency in December 2012. Analytik ...
analytica Vietnam 2013 – Platform for innovations
25-04-2013
For three days, high-quality laboratory equipment and the latest analysis devices were the focus of the third analytica Vietnam in Ho Chi Minh City. 114 exhibitors from ten countries presented their exhibits to more than 3,400 trade visitors. The content in the program of related events, ...
Promega and BASF develop alternative method on identifying allergenic substances
REACH requires tests for skin sensitizing action
12-04-2013
Promega and BASF have jointly developed an alternative method to animal studies that can reliably detect the allergenic potential of substances. Using a newly developed cell line, the reaction of skin cells to allergenic substances can now be demonstrated in the test tube. Allergic skin ...
Prosensa receives rare disease 'Company Award' from EURORDIS
12-03-2013
Prosensa received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels. The Black Pearl Gala Dinner is hosted annually by EURORDIS, a non-governmental alliance of patients and patient organizations active in the field of rare diseases, to celebrate Rare Disease Day. Awards ...
Sixth Merck Serono spin-off company to focus on gastrointestinal immunological disorders
05-03-2013
Merck Serono announced the creation of Calypso Biotech, the sixth spin-off company resulting from its Entrepreneur Partnership Program (EPP). Calypso Biotech was formed around Merck Serono’s R&D portfolio in the field of inflammatory bowel diseases, targeting selected niche indications with ...
Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy
04-03-2013
Trophos SA announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).The independent Data Monitoring Committee (DMC) has reviewed the treatment effect at one year on the primary outcome ...
Quinten identifies a combination of two synergistic markers that predicts a favorable response to treatment in breast cancer
27-02-2013
Quinten announced the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC). In the sub-group with both markers in combination, 86 per cent of women responded to ...
Circassia’s cat allergy treatment shows sustained symptom improvement
26-02-2013
Imperial Innovations Group plc announced that portfolio company Circassia has seen strong results from its follow up phase II clinical trial. Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® ...
Netmeeting
